The FDA has cleared the first glucose monitoring system designed specifically for weight management, developed by our partner, Signos. Unlike existing treatments such as GLP-1 drugs or bariatric surgery—which are often limited to patients with obesity—Signos’ system is available to anyone through a membership program. It combines an AI-powered platform with a Dexcom continuous glucose monitor (CGM) to provide real-time insights and personalized recommendations for healthier weight management.
This clearance offers a more accessible and affordable option compared to costly obesity drugs, which can exceed $1,000 per month and face supply challenges. With plans starting at $129 per month, Signos provides CGMs, app-based tracking, and tailored guidance to support weight goals. The system can also complement existing treatments, helping patients maintain progress after GLP-1 therapy or surgery. By bringing metabolic data to everyday users, Signos aims to help millions better understand their bodies and achieve long-term, sustainable weight management.